)
Primary Immune Deficiency (PID)
Have a Question? Use Our New Chat Feature! Chat with our Medical Information Specialists by clicking on the Chat with us now available in the lower right corner of this screen.
Posters
The HILO Study: High Volumes and Flow Rates of Subcutaneous IgPro20 Pump-assisted Infusions in Patients With Primary Immunodeficiency
Please see full prescribing information for Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid
Safety Profile of High IgPro20 Infusion Parameters in Patients With Primary Immunodeficiency (PID): Results From the Forced Upward Titration HILO Study
Please see full prescribing information for Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid
Feasibility of Subcutaneous IgPro20 Administration Via Manual Push at High Flow Rates in Patients With Primary Immunodeficiency: Findings of the HILO Study
Please see full prescribing information for Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid
Immunoglobulin Replacement Therapy in Patients with Immunodeficiencies - Impact of Administration Method on Patient-Reported Outcomes
High treatment satisfaction with Hizentra, a 20% subcutaneous immunoglobulin (SCIG): Real-world survey data
Real-world experience of a cohort of previously untreated PI patients on SCIG
Isoagglutinin Reduction in IVIg by Specific Immunoaffinity Chromatography Reduces Spontaneous Reporting Rates of Hemolytic Reactions
